BioAge Labs, Inc. 8-K

What Happened
BioAge Labs, Inc. filed an 8-K on June 12, 2026 reporting the results of its June 10, 2026 Annual Meeting of Stockholders. Stockholders elected three Class II directors — Patrick Enright, M.B.A.; James I. Healy, M.D., Ph.D.; and Rekha Hemrajani, M.B.A. — each to three-year terms expiring at the 2029 Annual Meeting. Shareholders also ratified the appointment of KPMG LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

Key Details

• Director elections (terms to expire at the 2029 Annual Meeting):
  • Patrick Enright: 30,075,928 shares for; 1,184,271 withheld; 5,327,405 broker non‑votes.
  • James I. Healy: 25,499,205 shares for; 5,760,994 withheld; 5,327,405 broker non‑votes.
  • Rekha Hemrajani: 27,826,781 shares for; 3,433,418 withheld; 5,327,405 broker non‑votes.
• Auditor ratification for FY2026: KPMG LLP approved with 36,561,171 shares for, 1,305 against, and 25,128 abstaining.
• Reported on Form 8-K and signed by CFO Dov Goldstein on June 12, 2026.

Why It Matters
For investors, these results confirm the company’s board composition for the next three years and finalize the independent auditor for FY2026 reporting. The vote tallies show the level of shareholder support and the presence of broker non‑votes on the director elections; ratification of KPMG is effectively unanimous. These are governance items that affect oversight and financial reporting going forward.